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Rat adipose tissue rapidly accumulates and slowly releases an 
orally-administered high vitamin D dose 
D. A. Janneke Brouwer", Jackelien van Beek, Harri Fenverda, Astrid M. Brugman, 
Fiona R. M. van der Klis, H. Jacoline van der Heiden and Frits A. J. Muskiet 
Central Laboratory for Clinical Chemistry, University Hospital Groningen, PO Box 30.001, 97 RB Groningen, 
The Netherlands 
(Received 29 May 1997-Revised ii December 1997-Accepted 22 December 1997) 
We investigated the effect of oral high-dose cholecalciferol on plasma and adipose tissue 
cholecalciferol and its subsequent release, and on plasma 25-hydroxyvitamin D (25(OH)D). 
Female Wistar rats (n 126) received 37.5 pg cholecalciferol/d for 14 d and were subsequently 
studied for a further 88 d. Two subgroups of eighteen rats each were fasted for 3 d immediately 
after treatment (days 14- 17) and at the end of the study (days 98- 101). During treatment, 
plasma cholecalciferol increased rapidly to reach a steady-state. Plasma 25(OH)D and adipose 
tissue cholecalciferol increased linearly for 1 - 2 d after treatment. Serum Ca and inorganic 
phosphate also increased. Subsequently half-lives of plasma cholecalciferol and 25(OH)D, and 
perirenal and subcutaneous adipose tissue were: 1.4, 22.5,97.5 and 80.9 d respectively. Fasting, 
as compared with ad libitum feeding, caused increased plasma free fatty acids, weight loss up to 
14 % and increased adipose tissue cholecalciferol (nmol/g wet weight). It did not affect plasma 
cholecalciferol immediately after cholecalciferol treatment, but raised plasma 25(OH)D. Fasting 
at the end of the study decreased plasma cholecalciferol and increased plasma 25(OH)D. We 
conclude that orally-administered cholecalciferol rapidly accumulates in adipose tissue and that 
it is very slowly released while there is energy balance. Fasting causes preferential loss of 
triacylglycerols from adipose tissue, as opposed to cholecalciferol, but nevertheless augments 
plasma 25(OH)D. Adipose tissue may act as a 'buffer to functional vitamin D status' by 
preventing, to a certain extent, unregulated production of 25(OH)D from dietary vitamin D, and 
by slowly releasing vitamin D under fasting conditions. 
Cholecalciferol: Plasma 25-hydroxyvitamin D: Calcium: Blood 
Adequate vitamin D status is essential for the prevention of 
rickets in children, and osteomalacia (Fraser, 1980) and 
probably osteoporosis (Compston, 1995) in adults. Based 
on, for example, the wide organ distribution of the vitamin 
D receptor, it is becoming increasingly clear that vitamin D 
metabolites are not only important in (bone) Ca homeo- 
stasis, but also for adequate functioning of many other 
systems (Reichel et al. 1989). 
Present vitamin D supplementation recommendations 
concern post-menopausal women (Dawson-Hughes et al. 
1991; Compston, 1995) and the elderly over 75 years (The 
Committee on Nutrition of the Elderly, Food and Nutrition 
Council, 1995) who live at high latitudes. These groups are 
recommended to take vitamin D supplements during 
winter. The daily dosage is, however, subject to discussion, 
because of remaining concern about (cumulative) toxicity 
(Schwartzman & Franck, 1987). 
Plasma 25-hydroxyvitamin D (25(OH)D) level is widely 
regarded as the most reliable index of vitamin D status. 
However, oral supplementation of adults with either 10 or 
20 pg cholecalciferol/d does not cause much difference in 
plasma 25(OH)D concentrations (Lips et al. 1988; van der 
Klis et al. 1996). On the basis of these results, it was 
suggested that adipose tissue functions as a vitamin D- 
buffering system that to a certain extent prevents 
uncontrolled synthesis of 25(OH)D in the liver (van der 
Klis et al. 1996). Mawer et al. (1972) had suggested 
previously that storage in tissue lipid may limit potential 
vitamin D toxicity, while Rosenstreich et al. (1971) 
suggested that slow release of vitamin D from adipose 
tissue may be an important factor in long-term vitamin D 
status. 
We investigated the effect of daily oral administration of 
high-dose (37.5 pg) cholecalciferol to rats on cholecalcif- 
Abbreviations: 25(OH)D, 25-hydroxyvitamin D. 
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erol accumulation in adipose tissue and its subsequent 
release into plasma under ad libitum feeding conditions and 
during short-term fasting. Cholecalciferol was administered 
for 14d and the levels of cholecalciferol in plasma and 
adipose tissue and of 25(OH)D in plasma were monitored 
from day 0 up to day 101. To promote adipose tissue 
mobilization, two subgroups of rats were fasted for 3d, 
immediately after cessation of cholecalciferol treatment 
and 84d after discontinuation of treatment. Serum Ca and 
phosphate were monitored to detect biochemical signs of 
vitamin D toxicity. 
Materials and methods 
Animals, vitamin D and chemicals 
Female Wistar rats, weighing 150- 180 g, were obtained 
from Harlan (Zeist, The Netherlands). They were housed 
under standard laboratory conditions (12 h dark- 12 h light, 
25") with free access to acidified tap water (pH 2.5 - 3) and 
standard rodent chow, unless otherwise stated. The standard 
chow contained 37.5 pg cholecalciferol/kg, corresponding 
to a daily background intake of about 0.75 pg cholecalcif- 
erol from the diet. Cholecalciferol (cholecalciferol densi- 
tosum oleosum, 50 mg/g) for administration was obtained 
from OPG (Utrecht, The Netherlands). For administration 
orally, it was diluted in arachid oil to 37.5 pg/ml. 
Chemicals for the analysis of cholecalciferol by HPLC 
were obtained from Merck (Darmstadt, Germany) and 
Rathburn (Brunswig Chemie, Amsterdam, The Nether- 
lands). Ergocalciferol and cholecalciferol standards for 
quantification were obtained from Sigma (St Louis, MO, 
USA). 
Experimental 
A group of 126 rats received orally 37.5 pg cholecalciferol 
(dissolved in 1 ml arachid oil) daily for 14d (days 0- 13) at 
22.00 hours. The last dose was administered 22.00 hours on 
day 13. Groups of six rats (a total of ninety rats) were killed 
at 10.00 hours under halothane anaesthesia on day 0 (i.e. 
before treatment), days 3,6, 9 and 12 (i.e. during treatment) 
and days 14, 15, 16, 17, 40, 76, 98, 99, 100 and 101 (i.e. 
after treatment). The rats were weighed and samples of 
blood were drawn from the aorta both in the presence (to 
permit coagulation) and absence of EDTA. Serum and 
EDTA-treated plasma were prepared by centrifuging for 
10min at 1700g and 4". Samples of perirenal and 
subcutaneous adipose tissue (about 1 - 2 g each) were 
removed, weighed, and frozen in liquid N2. Serum Ca 
and phosphate were measured immediately. Samples were 
stored at - 20" for the measurement of other variables. 
The remaining thirty-six rats were used for the study of 
vitamin D mobilization under fasting conditions on days 
15- 17 (eighteen rats) and days 99- 101 (eighteen rats). 
Eighteen rats were fasted from 12 h after the last dose of 
cholecalciferol (i.e. from 10.00 hours on day 14). They 
continued to have free access to tap water. Groups of six 
rats were subsequently killed at 10.00 hours on days 15, 16 
and 17, corresponding with fasting for 24, 48 and 72h 
respectively. Body weight was determined, and samples of 
blood and adipose tissue were collected and processed as 
described previously. The same protocol was used for the 
study of vitamin D mobilization on days 99- 101. Ad  
libitum-fed counterparts served as controls. They were 
killed at 10.00 hours on days 14, 15, 16 and 17, and days 
98,99, 100 and 101. 
Analyses 
Serum Ca and phosphate concentrations were determined 
using an MEGA automated analyser (Merck, Darmstadt, 
Germany). Plasma free fatty acid concentrations were 
determined in samples collected on days 15 - 17 and days 
99- 101, using an enzymic kit (Wako NEFA C kit; Wako 
Chemical, Neuss, Germany). 
Plasma 25-hydroxyergocalciferol and 25-hydroxychole- 
calciferol were measured as 25(OH)D by using a 
competitive radio-binding assay with 3H-labelled 25- 
hydroxycholecalciferol and vitamin D-binding protein from 
human serum after solid-phase extraction. Between-series 
CV at 16, 62 and 101nmol/l were 13, 12 and 13% 
respectively. 
Plasma and adipose tissue cholecalciferol levels were 
determined using reversed-phase HPLC with U.V. detection, 
following saponification, organic solvent extraction and 
further prepurification with straight-phase HPLC, essen- 
tially according to Thompson et al. (1982). Ergocalciferol 
served as an internal standard. In short, the sample (1.0 ml 
plasma, 1 g adipose tissue) was saponified overnight in 
ethanolic KOH at 70" and extracted with hexane. For 
adipose tissue samples, the hexane layer was washed 
consecutively with KOH (50 g/l) ethanol (300 ml/l) in 
saline (9 g NaC1/1) and saline. After evaporation to dryness 
at room temperature under a stream of N2, the residue was 
dissolved in 1.5 ml hexane, followed by cholesterol 
precipitation with methanolic digitonin. After centrifuga- 
tion, the hexane layer was collected, evaporated to dryness 
(at room temperature under N2), and redissolved in the 
straight-phase HPLC eluent (hexane - isopropanol; 
99.5:0.5, v/v). Isocratic elution of vitamin D was 
performed using a Waters M6000A pump (Waters, Milford, 
MA, USA) at a flow-rate of 1.5 ml/min, using a Spheri-5 
silica column (220 x 4.6mm; Brownlee Applied Biosys- 
tems, Foster City, CA, USA) and a Waters 486 tunable 
absorbance U.V. detector at 260nm. This system does not 
separate ergocalciferol and cholecalciferol. A cholecalci- 
ferol standard was used for the establishment of their 
retention time and their subsequent collection from sample 
extracts. The collected vitamin D fraction was evaporated 
to dryness (at room temperature under N2). The purified 
vitamin D extract was redissolved in the reversed-phase 
HPLC eluent (acetonitril - tetrahydrofuran - water; 
94 : 5 : 1, by vol). Separation and detection of ergocalcifer- 
01 and cholecalciferol was performed using a Waters 
M6000A pump at a flow-rate of 1.0 ml/min, using a Spheri- 
5 RP18 column (Brownlee) and a Waters 486 tunable 
absorbance U.V. detector at 260nm. Plasma (nmol/l) and 
adipose tissue (nmol/g wet weight) cholecalciferol levels 
were calculated by comparing the peak area ratios of 
ergocalciferol and cholecalciferol with those of equimolar 
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standards. The within-series precision for cholecalciferol in 
plasma was calculated by measurement of six samples of a 
human plasma pool on six different occasions. The overall 
mean plasma cholecalciferol concentration was 134 nmol/l 
and the mean within-series CV amounted to 3.4 (range 1.7 - 
7.7) %. The between-series precision and recovery were 
established by analysing a rat plasma pool with and without 
enrichment with 130 nmol cholecalciferol/l on four occa- 
sions. The mean endogenous cholecalciferol concentration 
amounted to 364 nmol/l (CV 2.7 %) and the mean recovery 
was 93.6 % (CV 11.6 %). The within-series precision of 
cholecalciferol in adipose tissue was measured by the 6- 
fold analysis of hog lard. The CV was 28.1 % at a mean 
cholecalciferol content of 32 pmol/g. The within-series 
recoveries were measured by enrichment of lard with 78, 
156, 234 and 312 pmol cholecalciferol/g. The recoveries 
(%; n 6) amounted to: 73-6 (CV 5.2 % at 78 pmol/g), 92.5 
(CV 3.9 % at 156pmol/g), 94.6 (CV 3.0 % at 234pmol/g) 
and 91.2 (CV 3.5 % at 312pmol/g). 
Data analyses 
Body weight was calculated relative to the body weight on 
day 14 and day 98 (start of fast) for fasting and ad libitum- 
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fed rats that were studied on days 15 - 17 and days 99 - 101 
respectively. Serum and adipose tissue half-lives were 
estimated using standard pharmacokinetic calculations, 
using a program developed by Dr H. Proost, Department 
of Pharmacy, University of Groningen. The calculations 
assumed 1 st-order kinetics without lag-time, one compart- 
ment and a multiple dosage regimen. Differences between 
groups were analysed using Student's t test (Stevens, 1980). 
ANOVA (Stevens, 1980) was used to determine steady- 
state conditions. P < 0.05 was considered significant. 
Results 
Fig. 1 shows the mean plasma cholecalciferol and 25(OH)D 
concentrations, together with the subcutaneous and peri- 
renal cholecalciferol levels before, during and after oral 
administration of cholecalciferol to rats. Cholecalciferol 
was given at 22.00 hours from day 0 to day 13 and samples 
were taken at 10.00 hours. Plasma cholecalciferol increased 
rapidly, to reach steady-state levels at day 3. After 
treatment, plasma cholecalciferol declined rapidly, with a 
calculated half-life of 1.4d. Levels at the end of the study 
(day 101, 31.3 (SD 1.5) nmol/l) were comparable with those 
on day 0 (31.8 (SD 2.3)nmol/l). Levels of 25(OH)D in 
o.o-' ' I I I I '  ' I ' 
0 10 20 30 40 50 60 70 80 90 100110 
Study period (d) 
Study period (d) Study period (d) 
Fig. 1. Time-courses of plasma cholecalciferol (a) and 25-hydroxyvitamin D (25(OH)D; (b)) and subcutaneous (c) and perirenal (d) adipose 
tissue cholecalciferol contents in rats, before, during and after supplementation with 37.5 pg cholecalciferol/d. Cholecalciferol was administered 
orally from day 0 to day 13 at 22.00 hours and samples were taken at 10.00 hours. (=), Supplementation period. Data points represent means 
with their standard errors, represented by vertical bars, for groups of six rats. For details of procedures, see p. 528. 
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plasma, and cholecalciferol in subcutaneous and perirenal 
adipose tissue increased linearly during treatment. They 
subsequently declined, with half-lives (d) of 22.5 (plasma 
25(OH)D), 80.9 (subcutaneous adipose tissue), and 97.4 
(perirenal adipose tissue). Plasma levels of 25(OH)D on 
day 101 (132 (SD ll)nmol/l) were below (P<O.OOOl) 
those on day 0 (225 (SD 8)nmol/l). Subcutaneous and 
perirenal adipose tissue cholecalciferol contents at the end 
of the study (0.77 (SD 0.03) and 0.65 (SD 0.02)nmol/g 
respectively) were above ( P  < 0.0001) those on day 0 (0.30 
(SD 0.04) and 0.24 (SD 0.03) nmol/g respectively). 
Serum Ca and phosphate concentrations increased from 
baseline (day 0) to the end of the treatment (day 14); levels 
were: Ca 2.51 (SD 0.15) v. 2.96 (SD 0.10) mmol/l ( P  = 
0.0001); phosphate 2.10 (SD 0.32) v. 2.69 (SD 0.32) mmol/l 
( P  = 0.001). Serum phosphate reached baseline levels 3 d 
after treatment (2.14 (SD 0.23) mmol/l, day 17). Serum Ca 
was still elevated 3d  after treatment (2.68 (SD 0.07) 
mmol/l, P = 0.035, day 17) and reached baseline levels by 
26 d after treatment (2.57 (SD 0.04) mmol/l, day 40). 
Fig. 2 shows plasma free fatty acid concentrations and 
the relative body weights of fasting and ad libitum-fed rats. 
Rats were fasted immediately after vitamin D treatment 
(days 14-17) and at about 3 months after its diswntinuation 
(days 98-101). Fasting rats had higher free fatty acid 
concentrations than their ad libitum-fed counterparts. 
Compared with the controls, fasted rats had lower relative 
body weights from 1 d after initiation of fasting. After a 3 d 
fast, they has lost 15.6% (days 14-17) and 13.0% (days 98- 
101) of their body weights; ad libitum-fed rats did not lose 
weight. 
Fig. 3 shows the changes in plasma cholecalciferol and 
25(OH)D concentrations, and in subcutaneous and perire- 
nal adipose tissue cholecalciferol contents in fasting and ad 
libitum-fed rats. Plasma cholecalciferol and 25(OH)D 
concentrations of each of the groups decreased (ANOVA, 
P < 0.05) from day 14 to day 17 and from day 98 to day 
101. When compared with ad libitum-fed rats, fasting rats 
showed no difference in plasma cholecalciferol concentra- 
tions from day 14 to day 17, but they had lower 
cholecalciferol concentrations from day 99 to day 101. 
Plasma 25(OH)D levels of fasting rats were higher on days 
16 and 17, and on day 101. 
In fasted rats cholecalciferol contents (nmol/g wet 
tissue) of subcutaneous and perirenal adipose tissues 
increased between day 14 and day 17, but not from day 
98 to day 101. Compared with ad libitum-fed rats, fasting 
rats had higher subcutaneous adipose tissue contents on 
days 16 and 17, and on days 100 and 101. Fasted rats had 
higher perirenai adipose tissue contents on days 17 and 101. 
Neither fasting period caused differences in serum Ca 
and phosphate concentrations between fasting and ad 
libitum-fed rats. 
Discussion 
We monitored the levels of cholecalciferol in plasma and 
adipose tissue of rats that received 37.5 pg chole- 
calciferol/d for 14d. This dose amounted to about fifty 
times their usual daily intake via the diet. The cumulative 
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Fig. 2. Time-courses of plasma free fatty acid concentrations and 
relative body weight (body weight relative to that on days 14 and 98; 
Yo), in fasting (0-0) and ad libifurnfed (0.' O) rats. All rats had 
previously received orally 37.5 pg cholecalciferoVd from day 0 to day 
13 at 22.00 hours. Rats were weighed and samples were taken at 
10.00 hours. Data points represent mean values with their standard 
errors represented by vertical bars for a group of six rats. $, The start 
of fasting (10.00 hours on days 14 and 98). Mean values for fasting 
rats were significantly different from those for ad libifurnfed rats: 
*P < 0.05. For details of procedures, see p. 528. 
tration we monitored plasma and adipose tissue cholecalci- 
ferol under ad libitum feeding conditions for another 88 d, 
and studied the effect of a 3 d fast in the period immediately 
after treatment and at the end of the study. We also 
measured plasma 25(OH)D, since vitamin D is rapidly 
converted into 25(OH)D when it reaches the liver. 
Furthermore, 25(OH)D is generally considered to be a 
reliable index of functional vitamin D status because 
25(OH)D has a long half-life and is the immediate 
precursor of 1,25-dihydroxyvitamin D. 
During treatment, plasma cholecalciferol showed a very 
rapid increase and a subsequent steady-state, whereas 
adipose tissue cholecalciferol and plasma 25(OH)D showed 
linear increases up to 1-2 d after discontinuation of 
cholecalciferol treatment (Fig. 1). The steadily increasing 
plasma 25(OH)D, in the absence of any change of plasma 
cholecalciferol, seems of particular importance, since it is 
generally believed that vitamin D toxicity is caused by the 
interaction of high concentrations 25(OH)D with the vitamin 
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Fig. 3. Time-courses of plasma cholecalciferol (a) and 25-hydroxyvitamin D (25(OH)D; (b)) concentrations and subcutaneous (c) and perirenal 
(d) adipose tissue cholcalciferol contents in fasting (0-0) and adlibiturnfed (0.. .O) rats. All rats had previously received 37.5 pg cholecalciferoll 
d from day 0 to day 13. Rats were weighed and samples were taken at 10.00 hours. Data points represent means with their standard errors 
represented by vertical bars, for a group of six rats. i, The last cholecalciferol administration (day 13, 22.00 hours) $, the start of fasting (10.00 
hours at days 14 and 98). Mean values for fasting rats were significantly different from those for ad libiturnfed rats: "P < 0.05. For details of 
procedures, see p. 528. 
D receptor. In agreement with this suggestion, we observed 
increases in serum Ca and inorganic phosphate during 
cholecalciferol treatment, while Ca levels at the end of the 
treatment (day 14; 2.96mmol/l) were close to those 
(3.3 mmol/l) reported for rats that,received toxic vitamin D 
doses (three oral doses of 2.5 mg; Swierczyliski et al. 1987). 
The steady increase in 25(OH)D at 37.5yg chole- 
calciferol/d seems to contrast with the observations of 
Lips et al. (1988) and van der Klis et al. (1996) in human 
subjects. From their studies, it can be concluded that 
healthy adults who receive 10 or 20 pg cholecalciferol/d 
show little or no difference in plasma 25(OH)D during 1 
year of treatment, and that steady-state levels are reached in 
1 week or less. The short-term conversion efficiency of 
orally-administered vitamin D to 25(OH)D may be 
dependent, therefore, on the vitamin D dose, and it is 
possible that above certain daily doses accumulation of 
25(OH)D in plasma cannot be avoided. It is conceivable 
that the underlying mechanism of plasma 25(OH)D 
accumulation is increasing vitamin D uptake by the liver, 
as opposed to storage in adipose tissue, causing increasing 
exposure of vitamin D to the poorly regulated (Holick, 
1994) hepatic 25-hydroxylase. A lower (physiological) 
vitamin D dose is likely, therefore, to exhibit different 
kinetics, and it also remains to be established whether 
present findings relating to a high dose can be extrapolated 
to human subjects. Ca and phosphate levels decreased 
rapidly after discontinuation of cholecalciferol administra- 
tion (data not shown) concomitant with the decreases in 
plasma cholecalciferol and 25(OH)D (Fig. 1). Calculated 
half-lives of plasma cholecalciferol and 25(OH)D were in 
agreement with those reported for human subjects by 
Mawer et al. (1969, 1971; cholecalciferol 1 d, 25(OH)D 
15 - 30 d). In contrast to plasma cholecalciferol and 
25(OH)D, adipose tissue cholecalciferol contents were still 
well above baseline levels at the end of the study. A similar 
pattern showing a gradual decrease after cessation of 
cholecalciferol administration was also reported by Rosen- 
streich (1971) and our calculated half-life was in agreement 
with their observation (81 d). It raised the question of 
whether adipose tissue vitamin D should be regarded as a 
slow-release pool that supports long-term functional 
vitamin D status (i.e. plasma 25(OH)D), and whether 
massive vitamin D release from adipose tissue, e.g. during 
fasting, may cause an increase in plasma 25(OH)D and 
toxicity, as suggested by Connors et al. (1976). 
Data in Fig. 1 show that the fifty times higher intake of 
cholecalciferol for 14d was unable to increase plasma 
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25(OH)D levels for longer than about 27 d after treatment, 
and that in this period only small changes occurred in 
adipose tissue cholecalciferol. Circulating 25(OH)D levels, 
therefore, seem particularly dependent on the continuous 
influx of vitamin D from the gastrointestinal tract, at least 
under the present condition of energy balance and level of 
vitamin D intake from the diet. 
A different situation occurs, however, during negative 
energy balance and zero dietary vitamin D intake, as 
indicated by the study of fasting and ad libitum-fed rats. 
Fasting, in contrast to ad libitum feeding, was associated 
with high free fatty acid concentrations in plasma and 
continuing weight loss (Fig. 2). As a result, adipose tissue 
cholecalciferol content (nmol/g wet weight) increased, 
apparently because of the preferential loss of triacylglycer- 
01s from adipose tissue, as opposed to the loss of 
cholecalciferol (Fig. 3). Fasting and ad libitum-fed rats 
showed no differences in plasma cholecalciferol concentra- 
tions in the period immediately after cholecalciferol 
treatment, but 25(OH)D levels of fasting rats were clearly 
higher. This shows that, despite their zero intake of vitamin 
D, fasting rats were able to increase their circulating 
25(OH)D levels, most probably by vitamin D mobilization 
from adipose tissue. The zero dietary vitamin D intake by 
fasting rats was reflected in their lower plasma vitamin D 
levels during the fasting period at the end of the study. Also 
these rats developed higher plasma 25(OH)D concentra- 
tions, although the difference was obviously less pro- 
nounced. 
We conclude that orally-administered cholecalciferol 
rapidly accumulates in adipose tissue and that it is only 
slowly released in periods of energy balance. Under these 
conditions circulating 25(OH)D levels may be dependent 
on dietary vitamin D intake and synthesis in skin. Fasting 
causes preferential loss of triacylglycerols (and possibly 
water) from adipose tissue, as opposed to vitamin D, but 
nevertheless augments plasma 25(OH)D levels under these 
conditions of zero dietary vitamin D intake. Toxicity 
because of massive vitamin D release and subsequent 
25(OH)D production does not take place. Adipose tissue is 
likely to act as a ‘buffer to functional vitamin D status’ by 
preventing unregulated production of 25(OH)D from 
dietary vitamin D up to a certain extent, and by slowly 
releasing vitamin D under ad libitum-fed and fasting 
conditions. 
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